FDA 483 - Trone Health Services, Inc. - November 21, 2017

During an inspection conducted from October 30 to November 21, 2017, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Trone Health Services, Inc. The inspection identified significant observations concerning the production of non-sterile drug products. The primary finding was the firm's use of non-pharmaceutical grade components. Specifically, Trone Health Services, Inc. utilized water as a component in various drug products, such as a dental gel and an oral rinse, without performing essential microbial and analytical testing. This lack of quality control for a critical ingredient raises concerns about product safety, quality, and efficacy. The FDA 483 document serves as a notice of inspectional observations, highlighting areas where the firm’s practices may not align with established good manufacturing practices. Trone Health Services, Inc. is required to respond to these observations by outlining corrective actions and preventative measures to ensure all components meet pharmaceutical standards and that manufacturing processes comply with regulatory requirements to safeguard public health.